SCYNEXIS Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
47.01 M |
Public Float |
34.43 M |
SCYNEXIS Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.65 |
Market Cap |
$69.21 M |
Shares Outstanding |
53.65 M |
Public Float |
46.83 M |
Address |
1 Evertrust Plaza Jersey City New Jersey 07302 United States |
Employees | - |
Website | http://www.scynexis.com |
Updated | 07/08/2019 |
SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. |